BofA Upgrades Edwards Lifesciences to Buy, Anticipates Strong Growth Ahead
Thursday, 7 March 2024, 19:12
Bank of America's Endorsement
Bank of America (BofA) has upgraded Edwards Lifesciences (EW) to a buy rating, expressing confidence in the company's future performance.
Positive Forecast
The upgrade suggests the company is expected to return to double-digit growth with sustained momentum.
The move by BofA highlights the strong potential for investors looking for growth opportunities in the healthcare sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.